Thank you, Mr. Chair.
I'll continue with questions for Mr. Giroux.
Mr. Giroux, I have here your analysis report on Bill C‑64. Under the heading “Sources of Uncertainty”, which is quite striking, it states the following: “The estimate has high uncertainty and is contingent on the number of drugs listed for coverage. Drug expenditures have several cost drivers and the projections are highly sensitive to the projected growth rate of those cost drivers….” You also mention “behavioural effects such as substitution from the drugs not listed on the formulary to the drugs [currently] on the formulary.”
I have a simple question for you. Could the number of drugs covered decrease after pharmacare is implemented?